309. Progressive myoclonus epilepsy Clinical trials / Disease details
Clinical trials : 11 / Drugs : 15 - (DrugBank : 2) / Drug target genes : 4 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00357669 (ClinicalTrials.gov) | November 2006 | 25/7/2006 | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults | A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (=16 Years) With Genetically Ascertained Unverricht-Lundborg Disease | Unverricht-Lundborg Disease | Drug: Brivaracetam 25 mg;Drug: Brivaracetam 50 mg;Other: Placebo | UCB Pharma SA | NULL | Completed | 16 Years | N/A | Both | 50 | Phase 3 | Finland;France;Italy;Netherlands;Réunion;Sweden;Tunisia |